The function of conserved amino acids in or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan

Molecular Immunology

Volumn 40, Issue 6, 2003, Pages 351-361

  Nakouzi, Antonio ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; CDR; Structure

Indexed keywords

AMINO ACID; FUNGUS ANTIBODY; GLUCURONOXYLOMANNAN; MANNAN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; GENETIC CONSERVATION; IMMUNOGLOBULIN VARIABLE REGION; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS;

FILOBASIDIELLA NEOFORMANS;

EID: 0141533222     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00149-4     Document Type: Article

References (35)

1. Adderson G.E., Shackelford P.G., Quinn A., Wilson P.M., Cunningham M.W., Insel R.A., Carroll W.L. Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J. Clin. Invest. 91:1993;2734-2743.
2. Beenhouwer, D.O., Valadon, P., May, R., Scharff, M.D., 2000. Peptide mimicry of the polysaccharide capsule of Cryptococcus neoformans. In: Cunningham, M.W., Fujinami, R.S. (Eds.), Molecular Mimicry, Microbes and Autoimmunity. ASM Press, Washington, pp. 143-160.
3. Bona C. Molecular characteristics of anti-polysaccharide antibodies. Springer Semin. Immunopathol. 15:1993;103-118.
4. Boswell C.M., Irwin D.C., Goodnight J., Stein K.E. Strain-dependent restricted VH and VL usage by antibacterial levan monoclonal antibodies. J. Immunol. 148:1992;3864-3872.
5. Casadevall A., Pirofski L. Adjunctive immune therapy for fungal infections. Clin. Infect. Dis. 33:2001;1048-1056.
6. L usage in polysaccharide binding antibodies. J. Exp. Med. 174:1991;151-160.
7. Casadevall A., DeShaw M., Fan M., Dromer F., Kozel T.R., Pirofski L. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:1994;3864-3872.
8. Casadevall A., Cleare W., Feldmesser M., Glatman-Freedman A., Goldman D.L., Kozel T.R., Lendvai N., Mukherjee J., Pirofski L., Rivera J., Rosas A.L., Scharff M.D., Valadon P., Westin K., Zhong Z. Characterization of a murine monoclonal antibody to Cryptocococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1998;1437-1446.
9. Cherniak R., Sundstrom J.B. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1994;1507-1512.
10. Cherniak R., Reiss E., Turner S. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103:1982;239-250.
11. Cleare W., Casadevall A. The different binding patterns of two IgM monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlates with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5:1998;125-129.
12. Dammers P.M., Kroese F.G.M. Evolutionary relationship between rat and mouse immunoglobulin IGHV5 subgroup genes (PC7183) and human IGHV3 subgroup genes. Immunogenetics. 53:2001;511-517.
13. Fleuridor R., Lees A., Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166:2001;1087-1096.
14. H genes encoding the immune response to β-(1,6)-galactan: somatic mutation in IgM molecules. EMBO J. 3:1984;3023-3030.
15. Juy D., Cazenave P.A. Igh restriction of the anti-α(1-3)dextran response: polyclonal B cell activators induce the synthesis of anti-α(1-3)dextran antibodies in lymphocytes from Igha mice only. J. Immunol. 135:1985;1239-1244.
16. . Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S., Foeller, C., 1991. Proteins of Immunological Interest. National Institute of Health Publication No. 91-3242, Bethesda, Maryland.
17. k genes by murine monoclonal antibodies against 3-fucosyllactosamine. Eur. J. Immunol. 19:1989;1741-1746.
18. MacGill T.C., MacGill R.S., Casadevall A., Kozel T.R. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans. J. Immunol. 164:2000;4835-4842.
19. Martin A.C.R. Accessing the Kabat sequence database by computer. Proteins Struct. Funct. Genet. 25:1996;130-133.
20. McLean G., Nakouzi A., Casadevall A., Green N.S. Human and murine immunoglobulin expression vector cassettes. Mol. Immunol. 37:2000;837-845.
21. Mitchell T.G., Perfect J.R. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:1995;515-548.
22. Mukherjee J., Casadevall A., Scharff M.D. Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J. Exp. Med. 177:1993;1105-1106.
23. Mukherjee J., Nussbaum G., Scharff M.D., Casadevall A. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181:1995;405-409.
24. Nakouzi A., Valadon P., Nosanchuk J.D., Green N.S., Casadevall A. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans that elicit protective and non-protective antibodies. Infect. Immun. 69:2001;3398-3409.
25. Nussbaum G., Anandasabapathy S., Mukherjee J., Fan M., Casadevall A., Scharff M.D. Molecular and idiotypic analysis of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and non-autoimmune mice. Infect. Immun. 67:1999;4467-4469.
26. Otteson E.W., Welch W.H., Kozel T.R. Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans. J. Biol. Chem. 269:1994;1858-1864.
27. Pawlita M., Potter M., Rudikoff S. Kappa-chain restriction in anti-galactan antibodies. J. Immunol. 129:1982;615-618.
28. Pirofski L. Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. Trends Microbiol. 9:2001;445-451.
29. Pirofski L., Lui R., DeShaw M., Kressel A.B., Zhong Z. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63:1995;3005-3014.
30. Sharon J. The invariant tryptophan in an H chain V region is not essential to antibody binding. J. Immunol. 140:1988;2666-2669.
31. Silverman G.J., Lucas A.H. Variable region diversity in human circulating antibodies specific for the capsular polysaccharide of Haemophilus influenzae type b. Preferential usage of two types of VH3 heavy chains. J. Clin. Invest. 88:1991;911-920.
32. Victor-Kobrin C., Manser T., Moran T.M., Imanishi-Kari T., Gefter M., Bona C.A. Shared idiotopes among antibodies encoded by heavy-chain variable region (VH) gene members of the J558 VH family as basis for cross-reactive regulation of clones with different antigen specificity. Proc. Natl. Acad. Sci. U.S.A. 82:1985;7696-7700.
33. Wiens G.D., Lekkerkerker A., Veltman I., Rittenberg M.B. Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect. J. Immunol. 167:2001;2179-2186.
34. Xu J.L., Davis M.M. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 13:2000;37-45.
35. Young A.C.M., Valadon P., Casadevall A., Scharff M.D., Sacchettini J.C. The three-dimensional structures of a polysaccharide binding antibody to Cryptococcus neoformans and its complex with a peptide from a phage display library: implication for the identification of peptide mimotopes. J. Mol. Biol. 274:1997;622-634.